• Optimizing CS/β-GP/HEC Hydrogels for 3D Culture

  2026-09-19

  Zhao et al. developed a structured screening strategy for injectable chitosan/β-glycerophosphate/hydroxyethyl cellulose hydrogels, integrating gelation, injectability, structural stability, and biological performance. The selected G1 and G3 formulations supported viable 3D growth, Huh7 tumor spheroid formation, and BMSC network organization, providing a practical framework for evaluating biomaterial formulations beyond single-parameter optimization.

• WRN–MSI Synthetic Lethality in Colorectal Cancer

  2026-09-18

  The reference study defines a p53/PUMA-dependent apoptotic mechanism underlying the selective vulnerability of mismatch repair-deficient, microsatellite-instable colorectal cancer cells to WRN helicase loss. Its genetic and xenograft evidence supports WRN as a therapeutic target while also showing why pharmacologic interpretation of ML216 requires careful distinction between WRN and BLM helicase biology.

• Antiarrhythmic Drugs and KCa2 Channels

  2026-09-18

  This study systematically tested ten antiarrhythmic drugs against human KCa2.2 and KCa2.3 channels using automated whole-cell patch clamp. Only dofetilide and propafenone inhibited these atrial-relevant potassium channels, and their relatively high in vitro IC50 values argue against clinically meaningful KCa2 channel inhibition at therapeutic exposure.

• Cardiogreen: Vascular Imaging to PDT

  2026-09-17

  Cardiogreen (Indocyanine green) combines vascular confinement and near-infrared optical behavior for cardiac, hepatic, and ophthalmic workflows. This guide translates its product parameters into reproducible PDT assays and shows how the reference study’s macrophage-phagocytosis framework can strengthen translational experimental design.

• Cepharanthine in Endometriosis: Organoids and Mice

  2026-09-17

  A 2026 study evaluated Cepharanthine across immortalized stromal cells, patient-derived endometriotic cells, endometrial organoids, and a murine peritoneal lesion model. Its main contribution is a cross-model mechanism linking reduced endometriosis growth with G0/G1 arrest, DNA damage, impaired repair, and mitochondrial apoptosis.

• Cyclosporin A: A Mechanistic Stress Test

  2026-09-16

  Cyclosporin A is more than an immunosuppressive reagent: it is a powerful pharmacological probe for testing how cyclophilin activity, mitochondrial permeability, calcineurin-NFAT signaling, and cell-death programs intersect. Using recent gouty arthritis research as an anchor, this article presents a translational framework for deploying cyclosporine in mechanistic experiments while recognizing its limits as a nonexclusive pathway perturbation.

• Celastrol, CAV-1, and Mitophagy in Liver Cancer

  2026-09-16

  A 2026 Phytomedicine study identifies the CAV-1/SCP2 axis as a regulator of mitochondrial cholesterol redistribution during celastrol treatment. By linking organelle-specific cholesterol accumulation to ROS, mitochondrial membrane-potential loss, mitophagy, and tumor suppression, the work proposes a distinct metabolic vulnerability in liver cancer models.

• EPZ-6438 Workflow for EZH2-Driven Cancer Models

  2026-09-15

  Build mechanism-linked experiments around EPZ-6438 by pairing H3K27me3 pharmacodynamic measurements with viability, cell-cycle, apoptosis, and gene-expression readouts. The workflow translates findings from HPV-associated cervical cancer into practical designs for malignant rhabdoid tumor models and EZH2-mutant lymphoma studies.

• CD80 mRNA as a Translational Costimulation Lever

  2026-09-15

  A mechanistic and strategic framework for using mouse CD80 mRNA to investigate antigen-presenting-cell costimulation, informed by clinical lessons from mRNA-augmented CAR T-cell therapy.

• WRN–MMR Synthetic Lethality in MSI Colon Cancer

  2026-09-14

  The reference PNAS study identifies p53 and PUMA-mediated apoptosis as the mechanism linking Werner helicase loss to selective killing of mismatch repair-deficient, microsatellite-unstable colorectal cancer cells. Its genetic, isogenic, pharmacological, and xenograft experiments show that TP53 status is a major determinant of response and provide a framework for interpreting RecQ helicase inhibitor studies.

• Bay 11-7821 for NF-κB Inflammation Research

  2026-09-14

  Bay 11-7821 (BAY 11-7082) provides a practical way to test whether IKK–NF-κB signaling connects pathogen recognition with cytokine release, apoptosis, or tumor-cell responses. This workflow combines pathway readouts, viability controls, and TLR2/TLR4-informed experimental design to distinguish mechanism from nonspecific toxicity.

• Cepharanthine N2771: Reliable Cell Assays

  2026-09-13

  A practical, evidence-based guide to using Cepharanthine (SKU N2771) in viability, proliferation, and apoptosis workflows. It connects solvent handling and product-quality checks with mechanistic evidence from stromal-cell, organoid, and animal models.

• PPT: Deconvolving ERα Signaling in LUAD

  2026-09-12

  PPT (Propyl Pyrazole Triol) can serve as a causal probe for separating ERα-driven transcription from correlated biomarkers in female lung adenocarcinoma. This guide connects selective receptor pharmacology with FOXM1–ERα network analysis, practical controls, and assay interpretation.

• PPACK Dihydrochloride in Thrombin Assays

  2026-09-11

  PPACK Dihydrochloride provides high-affinity, irreversible thrombin blockade for separating enzyme-driven coagulation from platelet receptor signaling. This guide translates its chemistry into practical assay workflows, control strategies, and troubleshooting steps for platelet aggregation and blood coagulation research.

• Chrysin, NOX2, and Ferroptosis in Dry Eye

  2026-09-11

  This 2026 study links NOX2-driven oxidative stress, corneal epithelial ferroptosis, and STING/NLRP3 inflammation in dry eye, positioning chrysin as a multitarget experimental intervention. Its combination of transcriptomic prioritization, ocular-surface models, fluorescent biochemical probes, and gene-overexpression rescue experiments provides a useful framework for mechanistic drug evaluation.

7956 records 1/531 page Next 12345 下5页 Last page